Bone Biologics

2 employees

Also known as:

bblg.us

bblg

BBLGW

bone biologics corp

Bone Biologics Corp. operates as a medical device company. engages in the research and development of bone regeneration in spinal fusion. Its product is Nell-1, which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. Its platform technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. The company was founded by Eric Kang Ting, Chia Soo and Benjamin Wu in 2004 and is headquartered in Burlington, MA.

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

N/A

Overview

Trial Phase Distribution

Phase

Trials

Not Applicable

100.0%

Trial Status Distribution

Recruiting

100.0%

Clinical Trials

Trials sponsored by this organization (1)

Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis

Not Applicable

Recruiting

interventional

Mar 202430 participants

Approvals

No approval data available

News

Bone Biologics Doubles Australian Trial Sites for NB1 Spinal Fusion Study, Targets Year-End 2026 Enrollment

- Bone Biologics has expanded its first-in-human pilot trial of NB1 to six Australian hospital sites, doubling the number of participating centers. - The multicenter, randomized study evaluates NB1 in up to 30 adults with degenerative disc disease undergoing transforaminal lumbar interbody fusion. - The company expects to complete patient enrollment by year-end 2026, with fusion success and Oswestry Disability Index change as primary endpoints. - A July 2026 private placement of roughly $3.0 million extends the company's operating runway through Q2 2027 to fund the clinical program.

Jul 25, 2026

Back to Organizations